Early myocardial injury biomarkers in diabetic hyperlipidemic rats: Impact of 10-dehydrogingerdione and vitamin D3

Elseweidy, Mohamed M.; Aly, Sousou I; Hammad, Sally K; Shershir, Noura I

doi:10.1177/1535370220943124

Cited by 4 publications

(2 citation statements)

References 78 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…70 The results demonstrated a significant rise in total cholesterol, triacylglycerol l, LDL-C, and VLDL-C levels and a marked decline in HDL-C levels in the positive control group compared to the negative control group at the end of the experimental period. These findings are consistent with those in other studies, 71,72 which reported that the levels of triacylglycerol, total cholesterol, LDL-C, and VLDL-C were significantly increased, and the HDL-C levels were declined considerably in diabetic hyperlipidemic rats because of the damaging effect of streptozotocin on b-cells and HFD consumption that results in reduced insulin secretion, hyperglycemia, and hyperlipidemia, while the groups treated with bee venom using both doses (0.5 and 1.23 mg/kg) and the combined therapy (metformin and atorvastatin) showed a significant decline in total cholesterol, triacylglycerol, LDL-C, VLDL-C levels, and a significant elevation in HDL-C levels in comparison to the positive control group at the end of the experimental period. The results are supported by other studies, 73,74 which revealed the ability of bee venom to alleviate lipid profile abnormalities through increasing insulin secretion and sensitivity in experimental animal models.…”

Section: Groupssupporting

confidence: 94%

Bee venom ameliorates cardiac dysfunction in diabetic hyperlipidemic rats

Zahran

Mohamad

Zein

2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

High levels of blood glucose and lipids are well-known risk factors for heart diseases. Bee venom is a natural product that has a potent hypoglycemic, hypolipidemic, anti-inflammatory, and antioxidant effects. The current study aimed to determine the bee venom effects on cardiac dysfunction compared to combined therapy of metformin and atorvastatin in diabetic hyperlipidemic rats. The median lethal dose of bee venom was estimated, and then 50 adult male albino rats were categorized into five groups. One group was fed a standard diet and served as a negative control, while the other groups were given nicotinamide and streptozotocin injections to induce type 2 diabetes. After confirming diabetes, the rats were fed a high-fat diet for four weeks. The four groups were divided as follows: one group served as a positive control, whereas the other three groups were treated with bee venom (0.5 mg/kg), bee venom (1.23 mg/kg), and combined therapy of metformin (60 mg/kg) and atorvastatin (10 mg/kg), respectively, for four weeks. Upon termination of the experiment, blood samples and heart tissue were obtained. Administration of bee venom using both doses (0.5 and 1.23 mg/kg) and combined therapy of metformin and atorvastatin revealed a significant decrease in the concentrations of glucose, total cholesterol, triacylglycerol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, troponin I, creatine kinase, and lactate dehydrogenase activities. Moreover, a significant decrease had been detedcted in malondialdehyde, nuclear factor-kappa-β levels, and relative mRNA expression of vascular cell adhesion molecule-1 and galectin-3 in heart tissue compared to the positive control ( P < 0.0001). Furthermore, there was a significant increase in bodyweight levels of insulin, high-density lipoprotein cholesterol, and total antioxidant capacity in heart tissue compared to the positive control ( P < 0.0001). The results indicate that bee venom can ameliorate cardiac dysfunction through attenuating oxidative stress and downregulating the NF-κβ signaling pathway.

show abstract

Section: Groupssupporting

confidence: 94%

Bee venom ameliorates cardiac dysfunction in diabetic hyperlipidemic rats

Zahran

Mohamad

Zein

2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…Furthermore, serum cholesterol and triglyceride levels decreased significantly in GLB- and GLB/vitamin D-treated diabetic groups than in the diabetic untreated animals, which was consistent with previous studies. 34 , 35 GLB has a hypolipidemic effect by inhibiting or reducing cholesterol biosynthesis, reducing fatty acid synthesis, and/or promoting the formation of triglyceride precursors such as acetyl CoA and glycerol phosphate. 25 On the other hand, Vitamin D can improve hyperlipidemia either indirectly by stimulating VDR, which helps in reducing acetylated low-density lipoprotein cholesterol uptake, or directly by stimulating lipogenesis through the activation of lipoprotein lipase in adipocytes.…”

Section: Discussionmentioning

confidence: 99%

Vitamin D Supplementation Could Enhance the Effectiveness of Glibenclamide in Treating Diabetes and Preventing Diabetic Nephropathy: A Biochemical, Histological and Immunohistochemical Study

Atia

Iqbal

Ahmed

et al. 2022

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

Diabetes mellitus is an oxidative stress-related disease characterized by hyperglycemia and a variety of complications, including nephropathy. Vitamin D has variable functions extending beyond the calcium metabolism to prevent oxidative tissue damage. We aimed to investigate whether vitamin D supplements could enhance Glibenclamide's effectiveness in treating diabetes and minimize the risk of associated pathology. Wistar rats were divided into normal control (n = 10) and diabetic (n = 30), where animals received two low doses of Streptozotocin 30 mg/kg/BW intraperitoneally to develop diabetes. The diabetic rats were then randomly divided into three equal groups: untreated, treated with Glibenclamide (0.6 mg/kg), and treated with Glibenclamide and Vitamin D3 (500 IU/kg). After eight weeks, the animals were sacrificed, and blood samples and kidney tissues were collected to evaluate biochemical, anti-oxidant, and pro-inflammatory cytokine levels and histological and immunohistochemical changes. Diabetic animals had significantly increased fasting blood glucose, lipid profile, blood urea, serum creatinine, and Malondialdehyde levels, whereas serum insulin, albumin, and the anti-oxidant enzymes superoxide dismutase and catalase were significantly decreased compared to normal control (p < 0.01). Furthermore, some renal histological changes were observed together with significantly increased immunoreactivity of anti-p53, anti-TNF-α, and anti-IL-6 antibodies when compared to the normal control. All abnormal parameters improved significantly with Glibenclamide therapy (p < 0.01), but combination therapy with vitamin D produced a much better result. In conclusion, vitamin D supplementation along with anti-diabetic medication can help prevent or reduce the severity of diabetic nephropathy due to its potent antioxidant, anti-inflammatory, and anti-apoptotic properties.

show abstract